Zusammenfassung
Urologika werden bei der Behandlung von Harnwegsinfektionen, Prostataleiden und anderen urologischen Störungen angewendet. In dieser Gruppe gehören 49 Präparate zu den meistverordneten Arzneimitteln (Tabelle 45.1). Die Verordnungen sind in der gesamten Indikationsgruppe erneut deutlich gefallen, Umsätze und verordnete Tagesdosen sind dagegen gestiegen. Die Verordnung therapeutisch fragwürdiger Präparate ist auch 1997 zurückgegangen. Sinnvolle Prostatamittel haben weiter zugenommen, die phytotherapeutischen Prostatamittel und sonstigen Urologika waren dagegen rückläufig (Abbildung 45.1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Appell R. A. (1997): Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 50(Suppl. 6A): 90–96.
Berges R. R., Windeier H., Trampisch H. J., Senge T. and the ß-sitosterol study group (1995): Randomised, placebo-controlled, double-blind clinical trial of ß-sitosterol in patients with benign prostatic hyperplasia. Lancet 345: 1529–1532.
Bhatia N. N., Karram M. M., Bergman A., Evans R. P. (1992): Antibiotic prophylaxis following lower urinary tract instrumentation. Urology 39: 583–585.
Bundesgesundheitsamt (1994): Aufbereitungsmonographie Uvae ursi folium (Bärentraubenblätter). Bundesanzeiger Nr. 109, S. 6213, 15.6.1994.
Caine M., Raz S., Ziegler M. (1975): Adrenergic and cholinergic receptors in the human prostate., prostatic capsule, and bladder neck. Brit. J. Urol. 27: 193–202.
Chappie C. R. (1996): Selective aradrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur. Urol. 29: 129–144.
Cobb M. M., Salen G., Tint G. S. (1997): Comparative effect of dietary sitosterol on plasma sterols and cholesterol and bile acid synthesis in a sitosterolemic homozygote and hétérozygote subject. J. Am. Coll. Nutr. 16: 605–613.
Flanigan R. C., Reda D. J., Wasson J. H., Anderson R. J., Abdellatif M., Bruskewitz R. C. (1998): 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J. Urol. 160: 12–16.
Foglar R., Shibata K., Horie K., Hirasawa A., Tsujimoto G. (1995): Use of recombinant a1adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur. J. Pharmacol. 288: 201–207.
Gormley G. J., Stoner E., Bruskewitz R. C., Imperato McGinley J., Walsh P. C. et al. (1992): The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med. 327: 1185–1191.
Iselin C. E., Schmidlin F., Borst E, Rohner S., Graber P. (1997): Oxybutynin in the treatment of early detrusor instability after transurethral resection of the prostate. Brit. J. Urol. 79: 915–919.
Klippel K. E, Hiltl D. M., Schipp B. (1997): A multicentric, placebo-controlled, double-blind clinical trial of ß-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. Brit. J. Urol. 80: 427–432.
Lepor H., Williford W O., Barry M. J., Brawer M. K., Dixon C. M. et al. (1996): The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N. Engl. J. Med. 335: 533–539.
Malinverni R., Hoigné R., Sonntag R. (1996): Sulfonamides, other folic acid antagonists and miscallaneous antibacterial drugs. In: Dukes M.N.G. (ed.): Meyler’s side effects of drugs. 13th ed. Elsevier, Amsterdam Lausanne New York Oxford Shannon Tokyo, pp. 843–871.
Moore K. H., Hay D. M., Imrie A. E., Watson A., Goldstein M. (1990): Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Brit. J. Urol. 66: 479–485.
Ouslander J. G., Blaustein J., Connor A., Pitt A. (1988): Habit training and oxybuty-nin for incontinence in nursing home patients: a placebo-controlled trial. J. Am. Geriatr. Soc. 36: 40–46.
Ouslander J. G., Schnelle J. R, Uman G., Fingold S., Nigam J. G. et al. (1995): Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. J. Am. Geriatr. Soc. 43: 610–617.
Riva D., Casolati E. (1984): Oxybutynin chloride in the treatment of female idio-pathic bladder instability. Results from double blind treatment. Clin. Exp. Obst. Gyn. 11: 37–42.
Schlager T. A., Anderson S., Trudell J., Hendley J. O. (1998): Nitrofurantoin prophylaxis for bacteriuria and urinary tract infection in children with neurogenic bladder on intermittent catheterization. J. Pediatr. 132: 704–708.
Simon C., Stille W. (1997): Antibiotika-Therapie in Klinik und Praxis. 9. Aufl., Schattauer, Stuttgart New York, S. 194–195, 211-214.
Snyder R., Witz G., Goldstein B. D. (1993): The toxicology of benzene. Environ. Health Perspect. 100: 293–306.
Stöhrer M., Bauer P., Giannetti B. M., Richter R., Burgdörfer H., Mürtz G. (1991): Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. Urol. Int. 47: 138–143.
Susset J. G., Tessier C. D., Wincze J., Bansal S., Malhotra C., Schwacha M. G. (1989): Effect of yohimbine hydrochloride on erectile impotence: A double-blind study. J. Urol. 141: 1360–1363.
Szonyi G., Collas D. M., Ding Y Y, Malone-Lee J. G. (1995): Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 24: 287–291.
Tapp A. J. S., Cardozo L. D., Versi E., Cooper D. (1990): The treatment of detrusor instability in postmenopausal women with oxyxbutynin chloride: a double blind placebo controlled study. Brit. J. Obstet. Gynaec. 97: 521–526.
Thüroff J. W., Bunke B., Ebner A., Faber P., de Geeter P. et al. (1991): Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J. Urol. 145: 813–817.
Wehnert J., Sage S. (1992): Therapie der Blaseninstabilität und Urge-Inkontinenz mit Propiverin hydrochlorid (Mictonorm®) und Oxybutyninchlorid (Dridase®)-eine randomisierte Cross-over-Vergleichsstudie. Akt. Urol. 23: 7–11.
Zorzitto M. L., Holliday P. J., Jewett M. A. S., Herschorn S., Fernie G. R. (1989): Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study. Age Ageing 18: 195–200.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schmitz, W. (1999). Urologika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 1998. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-58436-7_46
Download citation
DOI: https://doi.org/10.1007/978-3-642-58436-7_46
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-65207-6
Online ISBN: 978-3-642-58436-7
eBook Packages: Springer Book Archive